Danaher Co. (NYSE:DHR) Stake Lessened by Forsta AP Fonden

Forsta AP Fonden trimmed its holdings in Danaher Co. (NYSE:DHR) by 5.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 153,522 shares of the conglomerate’s stock after selling 8,700 shares during the period. Forsta AP Fonden’s holdings in Danaher were worth $35,241,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher during the third quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new position in Danaher during the 3rd quarter worth $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the 3rd quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Stephens reaffirmed an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Royal Bank of Canada cut their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.81.

Danaher Trading Down 1.1 %

NYSE:DHR opened at $247.77 on Wednesday. The firm has a market cap of $178.96 billion, a price-to-earnings ratio of 47.29, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a 50-day moving average price of $236.09 and a two-hundred day moving average price of $253.66.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter in the prior year, the business posted $2.09 earnings per share. On average, equities analysts expect that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.